Your browser doesn't support javascript.
loading
Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.
Alejos, Belén; Suárez-García, Inés; Rava, Marta; Bautista-Hernández, Azucena; Gutierrez, Félix; Dalmau, David; Sagastagoitia, Iñigo; Rivero, Antonio; Moreno, Santiago; Jarrín, Inma.
Afiliação
  • Alejos B; Institute of Health Carlos III, Centro Nacional de Epidemiología, Madrid, Spain.
  • Suárez-García I; Hospital Infanta Sofia, Madrid, Spain.
  • Rava M; Institute of Health Carlos III, Centro Nacional de Epidemiología, Madrid, Spain.
  • Bautista-Hernández A; Hospital Universitario de La Princesa, Madrid, Spain.
  • Gutierrez F; Hospital General Universitario De Elche, Elche, Spain.
  • Dalmau D; Hospital Universitari MutuaTarrassa, Tarrasa, Spain.
  • Sagastagoitia I; Hospital Clínico San Carlos, Madrid, Spain.
  • Rivero A; Hospital Reina Sofía, Córdoba, Spain.
  • Moreno S; Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain.
  • Jarrín I; Institute of Health Carlos III, Centro Nacional de Epidemiología, Madrid, Spain.
J Antimicrob Chemother ; 75(10): 3004-3014, 2020 10 01.
Article em En | MEDLINE | ID: mdl-32667674
ABSTRACT

OBJECTIVES:

We compared 48 week effectiveness and safety of first-line antiretroviral regimens.

METHODS:

We analysed HIV treatment-naive adults from the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) starting the most commonly used antiretroviral regimens from 2014 to 2018. We used multivariable regression models to assess the impact of initial regimen on (i) viral suppression (VS) (viral load <50 copies/mL); (ii) change in CD4 cell count; (iii) CD4/CD8 normalization (>0.4 and >1); (iv) CD4 percentage normalization (>29%); (v) multiple T-cell marker recovery (MTMR CD4 > 500 cells/mm3 plus CD4 percentage >29% plus CD4/CD8 > 1); (vi) lipid, creatinine and transaminase changes; and (vii) discontinuations due to adverse events (AE).

RESULTS:

Among 3945 individuals analysed, the most frequently prescribed regimens were ABC/3TC/DTG (34.0%), TAF/FTC/EVG/CBT (17.2%), TDF/FTC + DTG (11.9%), TDF/FTC/EVG/CBT (11.7%), TDF/FTC/RPV (11.5%), TDF/FTC + bDRV (8.3%) and TDF/FTC + RAL (5.3%). At 48 weeks, 89.7% of individuals achieved VS with no significant differences by initial regimen. CD4 mean increase was 257.8 (249.3; 266.2) cells/mm3, and it was lower with TAF/FTC/EVG/CBT and TDF/FTC/RPV compared with ABC/3TC/DTG. CD4 percentage normalization was less likely with TAF/FTC/EVG/CBT, and MTMR was less likely with TAF/FTC/EVG/CBT and TDF/FTC + RAL. The proportion of discontinuations due to AE was higher with TDF/FTC + bDRV (9.7%), followed by TDF/FTC/EVG/CBT (9.5%) and TDF/FTC + DTG (7.9%). Compared with ABC/3TC/DTG, cholesterol and LDL mean increases were higher with TAF/FTC/EVG/CBT and lower with TDF/FTC + DTG, TDF/FTC/RPV and TDF/FTC + RAL. Higher mean increases in triglycerides were significantly associated with TAF/FTC/EVG/CBT. Regimens containing DTG showed higher creatinine increases.

CONCLUSIONS:

The significantly greater immunological response and safety of some combinations may be useful for making decisions when initiating treatment.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome da Imunodeficiência Adquirida / Fármacos Anti-HIV Tipo de estudo: Clinical_trials / Etiology_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome da Imunodeficiência Adquirida / Fármacos Anti-HIV Tipo de estudo: Clinical_trials / Etiology_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha